Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China

被引:6
|
作者
Meng, Fan-Ya [1 ,2 ,3 ]
Sun, Yong [3 ]
Shen, Yong-Gang [3 ]
Pan, Hai-Feng [1 ,2 ]
Tang, Ji-Hai [3 ]
Wang, Bin-Bing [3 ]
Wu, Chang-Hao [4 ]
Ye, Dong-Qing [1 ,2 ]
机构
[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China
[2] Key Lab Major Autoimmune Dis, Hefei, Anhui, Peoples R China
[3] Anhui Ctr Dis Control & Prevent, Dept Immunizat & Prevent, Hefei, Anhui, Peoples R China
[4] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England
来源
PLOS ONE | 2017年 / 12卷 / 02期
基金
英国生物技术与生命科学研究理事会;
关键词
EVENT FOLLOWING IMMUNIZATION; CASE-DEFINITION; DATA-COLLECTION; FEBRILE SEIZURES; GUIDELINES; ELIMINATION; CHILDREN; AGE; FEVER;
D O I
10.1371/journal.pone.0172108
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The safety of measles vaccination is of great interest and importance to public health practice and the general society. We have analyzed the adverse events following immunization (AEFIs) of currently used measles-containing vaccines (including live attenuated measles vaccine, live attenuated measles and rubella combined vaccine, live attenuated measles and mumps combined vaccine, live attenuated Measles, Mumps and Rubella Combined Vaccine) in Anhui Province, China. From 2009 to 2014, 9.9 million doses of measles-containing vaccines were administrated and 1893 AEFIs were found (191.4 per million doses), of which, 33 serious AEFIs (3.3 per million vaccine doses) were reported. 59.4% (1124 cases) were male cases, and 85.1% (1611 cases) occurred in persons aged < 1 year. 93.3% (1766 cases) occurred at the first dose of vaccination and 95.9% (1815 cases) were found within 3 days after vaccination. This study presents up-to-date data and suggests that the measles-containing vaccines used in Anhui Province of China are safe.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] POST-MARKETING SURVEILLANCE OF NEW MEDICINES
    SMITHELLS, RW
    [J]. BRITISH MEDICAL JOURNAL, 1977, 2 (6096): : 1218 - 1218
  • [42] POST-MARKETING SURVEILLANCE BY DRUG MANUFACTURERS
    不详
    [J]. LANCET, 1988, 2 (8617): : 977 - 977
  • [43] Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
    Tavares-Da-Silva, Fernanda
    Mahaux, Olivia
    Van Holle, Lionel
    Haguinet, Francois
    Seifert, Harry
    Stegmann, Jens-Ulrich
    [J]. DRUG SAFETY, 2020, 43 (12) : 1223 - 1234
  • [44] WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
    Rubin, David T.
    Modesto, Irene
    Vermeire, Severine
    Danese, Silvio
    Ng, Siew C.
    Kwok, Kenneth K.
    Koram, Nana
    Jones, Thomas V.
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S36 - S36
  • [45] Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis
    Rubin, David T.
    Modesto, Irene
    Vermeire, Severine
    Danese, Silvio
    Ng, Siew C.
    Kwok, Kenneth K.
    Koram, Nana
    Jones, Thomas, V
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (03) : 302 - 310
  • [46] Post-marketing safety surveillance of erenumab: new insight from Eudravigilance
    Liang, David
    Sessa, Maurizio
    [J]. EXPERT OPINION ON DRUG SAFETY, 2022, 21 (09) : 1205 - 1210
  • [47] Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
    Chunxiao Li
    Tao Xu
    Peng Zhou
    Junhua Zhang
    Ge Guan
    Hui Zhang
    Xiao Ling
    Weixia Li
    Fei Meng
    Guanping Liu
    Linyan Lv
    Jun Yuan
    Xuelin Li
    Mingjun Zhu
    [J]. BMC Complementary and Alternative Medicine, 18
  • [48] Post-Marketing Surveillance of Prescription Drug Safety: Past, Present, and Future
    Chen, Brian K.
    Yang, Y. Tony
    [J]. JOURNAL OF LEGAL MEDICINE, 2013, 34 (02) : 193 - 213
  • [49] Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
    Li, Chunxiao
    Xu, Tao
    Zhou, Peng
    Zhang, Junhua
    Guan, Ge
    Zhang, Hui
    Ling, Xiao
    Li, Weixia
    Meng, Fei
    Liu, Guanping
    Lv, Linyan
    Yuan, Jun
    Li, Xuelin
    Zhu, Mingjun
    [J]. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
  • [50] Post-marketing surveillance of novel foods
    Warner, JO
    [J]. PEDIATRIC ALLERGY AND IMMUNOLOGY, 2002, 13 (06) : 385 - 385